Smoking and Hypertension Drive Dry Mouth Risk, Review Warns Dentists and Doctors
Dry mouth, medically known as xerostomia, is emerging as a significant but often overlooked health issue among people with hypertension who smoke. A comprehensive literature review by Ana Medawati, Sri Utami, and Intan Wahyu Aisyah from Universitas Muhammadiyah Yogyakarta shows that the combined effects of high blood pressure, long-term antihypertensive medication, and smoking substantially increase the risk and severity of xerostomia. The study was published in 2026 in the International Journal of Integrative Sciences and highlights important implications for oral health care, chronic disease management, and patient quality of life.
The findings matter because hypertension and smoking are both widespread, especially among adults and older populations. When these factors overlap, patients face a higher likelihood of dental decay, oral infections, difficulty eating and speaking, and a measurable decline in daily comfort. The review positions xerostomia not as a minor side effect, but as a clinical condition requiring coordinated medical and dental attention.
Why Dry Mouth Has Become a Growing Concern
Xerostomia refers to the persistent sensation of a dry mouth, usually linked to reduced saliva production. Saliva plays a critical role in protecting teeth, controlling oral bacteria, and supporting normal speech and swallowing. When saliva flow drops, the mouth becomes vulnerable to cavities, gum disease, fungal infections, and chronic discomfort.
The authors explain that xerostomia is increasingly reported among people with chronic systemic diseases. Hypertension stands out because it often requires lifelong medication, and many commonly prescribed drugs affect the body’s fluid balance and nervous system regulation. Smoking further compounds the problem by damaging salivary glands and reducing blood flow in oral tissues.
In this context, dry mouth becomes a convergence point between cardiovascular disease, lifestyle habits, and oral health outcomes.
How the Review Was Conducted
Rather than relying on a single clinical trial, the authors examined a wide body of existing scientific evidence. They reviewed studies published up to August 2025 using major international databases, including PubMed, Science Direct, and leading medical and dental publishers.
The review focused on:
1. Adults with hypertension
2. Use of antihypertensive medications such as diuretics, beta-blockers, ACE inhibitors, and ARBs
3. Smoking habits, including conventional and electronic cigarettes
4. Measured saliva flow rates and patient-reported dry mouth symptoms
Only peer-reviewed human studies and systematic reviews were included, ensuring that conclusions were drawn from clinically relevant evidence.
Key Findings: A Compounded Health Risk
Across multiple studies, the pattern is consistent: hypertensive patients who smoke experience dry mouth more frequently and more severely than non-smokers or people without hypertension.
The review highlights several important findings:
Dry mouth affects an estimated 20–40% of the general population, but rates are higher among hypertensive patients, particularly those taking multiple medications.
2. Medication effects on saliva
Diuretics and beta-blockers are most strongly associated with reduced saliva flow. Some studies report a 15–40% decrease in salivary flow rate among users of these drugs.
3. Smoking as a consistent risk factor
Evidence linking smoking to reduced saliva production is strong and consistent. Smokers show lower saliva flow, altered saliva composition, and higher subjective dry mouth scores than non-smokers.
Patients who combine hypertension, xerogenic medications, and smoking habits face greater reductions in saliva and higher risks of complications than those with only one risk factor.
These combined effects increase the likelihood of dental caries, oral candidiasis, periodontal disease, and impaired oral health–related quality of life.
What Happens Inside the Body
The review explains the biological mechanisms behind these findings in accessible terms. Antihypertensive drugs can reduce body fluid levels and alter nerve signals that stimulate saliva production. Smoking introduces nicotine and toxic substances that constrict blood vessels, increase oxidative stress, and damage salivary gland tissue.
When these mechanisms operate together, saliva production drops further, and the mouth’s natural defense system weakens. Over time, this leads to chronic oral health problems that may go unnoticed until they become severe.
Practical Implications for Patients and Providers
The authors stress that managing xerostomia in hypertensive smokers requires more than symptom relief. It calls for a comprehensive and multidisciplinary approach.
Recommended strategies include:
a. Lifestyle changes, especially smoking cessation and adequate hydration
b. Review of antihypertensive therapy, with attention to drugs known to reduce saliva
c. Non-pharmacological aids, such as sugar-free or xylitol-containing gum to stimulate saliva
d. Local treatments, including artificial saliva and protective oral gels
Medications that stimulate saliva production can help severe cases, but the review cautions that they must be used carefully in patients with cardiovascular conditions.
Ana Medawati and colleagues emphasize that dentists and physicians should work together. Dry mouth, they note, is often the first visible sign of a deeper interaction between chronic disease, medication, and lifestyle.
Author Profiles
Ana Medawati, DDS, M.Sc., Universitas Muhammadiyah Yogyakarta.Sri Utami, DDS, M.Sc. Universitas Muhammadiyah Yogyakarta.
Intan Wahyu Aisyah, DDS, Universitas Muhammadiyah Yogyakarta.
0 Komentar